FDA 483 - Covance by Labcorp - May 20, 2021

An FDA inspection of Covance by Labcorp in Durham, NC, a Contract Research Organization, revealed a failure to ensure proper monitoring of a clinical study. Approximately 100 protocol deviations, some deemed "important," were not identified in a timely manner. These issues impacted subject safety, regulatory compliance, and data integrity.